CRISPR injection could rewrite the future of blood pressure control

NCT ID NCT07758634

Recruiting now Disease control Sponsor: CRISPR Therapeutics AG Source: ClinicalTrials.gov ↗

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This trial tests an experimental therapy called CTX340, which uses CRISPR gene editing to disable a gene in the liver that regulates blood pressure. It is designed for adults with uncontrolled hypertension despite taking multiple blood pressure medications. The study will first assess safety and tolerability, then measure how well the treatment lowers blood pressure and reduces the target protein.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CTX340, a CRISPR-based gene editing therapy delivered via lipid nanoparticles to disrupt the angiotensinogen gene in the liver
What this could lead to: If successful, this could lead to a one-time treatment that durably lowers blood pressure, potentially reducing the need for daily pills.
What could go wrong: This is an early, first-in-human trial, so safety and effectiveness are unproven. Gene editing carries risks like off-target effects or unintended immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTENSION

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Research Site 1
RECRUITING

Port Orange, Florida, 32127, United States
Research Site 2
RECRUITING

Melbourne, 3168, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.